【摘要】 目的　以利培酮为对照 ,探讨奎硫平治疗精神分裂症的疗效和副作用。方法　将 79例符合CCMD 3诊断标准的精神分裂症病人随机分为两组 ,分别给予奎硫平和利培酮治疗 8周。采用阳性症状和阴性症状量表 (PANSS)评定临床疗效 ,副反应量表 (TESS)评定副反应。结果　治疗 8周后的疗效近似 (P >0 0 5 ) ;奎硫平组和利培酮组的显效率差异无显著性 (P >0 0 5 ) ;奎硫平组的副反应发生率低于利培酮组 ,但差异无显著性 (P >0 0 5 )。利培酮组锥体外系副反应和内分泌改变的发生均明显高于奎硫平组 (P <0 0 5 )。结论　奎硫平和利培酮对精神分裂症的疗效相当 ,副作用较小。更多还原

【Abstract】 Objective: To investigate the clinical efficacy and side effects of quetiapine in the treatment of schizophrenia. Methods: 79 patients with schizophrenia by CCMD-3 were randomly allocated to two groups treated with quetiapine or risperidone for 8 weeks. The Positive and Negative Syndrome Scale (PANSS) and Treatment Emergent Symptoms Scale (TESS) were used to evaluate efficacy and adverse effects respectively before and at the ends of 2,4,8 weeks of treatment. Results: The therapeutic efficacy in quetiapine group was similar to that in risperidone (P>0.05); There was no significant difference between the two groups (P>0.05). Incidence of adverse effects in the quetiapine group was lower than that in the risperidone group, but the difference was not significant (P>0.05). The rates of extra-pyramidal symptoms and endocrine change were significantly higher in the risperidone group than those in the quetiapine group. Conclusion: The results suggest that quetiapine is as effective as risperidone for the treatment of schizophrenia, but these side effects are different.更多还原